Table of Contents
<< Previous Issue | Feb 2009 (Vol: 2009, Issue: 2) | Next Issue >> |
- Section: Editorial
-
Who’s next for a mega merger?
- Section: Licensing
-
GSK Licenses Idenix’s HIV Drug
-
Novartis Pays US$75 M for Portola's Anticoagulant
-
Shire to Enter European ADHD Market
-
Merck Serono Signs Multiple Sclerosis Deal with Ambrx
- Section: Mergers & Acquisitions
-
Lundbeck to Buy US-based Ovation
-
Merck Makes Further Inroads into Biologicals
- Section: Research & Development
-
Dyax and Biogen Idec Expand Drug Discovery Deal